ZA964763B - Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists - Google Patents

Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Info

Publication number
ZA964763B
ZA964763B ZA964763A ZA964763A ZA964763B ZA 964763 B ZA964763 B ZA 964763B ZA 964763 A ZA964763 A ZA 964763A ZA 964763 A ZA964763 A ZA 964763A ZA 964763 B ZA964763 B ZA 964763B
Authority
ZA
South Africa
Prior art keywords
diones
substituted quinoxaline
receptor antagonists
cyclic amine
glutamate receptor
Prior art date
Application number
ZA964763A
Other languages
English (en)
Inventor
Brian Edward Kornberg
Sham Nikam
Michael Francis Rafferty
Po-Wai Yuen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA964763B publication Critical patent/ZA964763B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA964763A 1995-06-07 1996-06-06 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists ZA964763B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/474,877 US5874426A (en) 1995-06-07 1995-06-07 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
ZA964763B true ZA964763B (en) 1997-01-08

Family

ID=23885306

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964763A ZA964763B (en) 1995-06-07 1996-06-06 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Country Status (15)

Country Link
US (1) US5874426A (da)
EP (1) EP0830348B1 (da)
JP (1) JP3734275B2 (da)
KR (1) KR19990022482A (da)
AT (1) ATE223387T1 (da)
AU (1) AU713993B2 (da)
CA (1) CA2220076A1 (da)
DE (1) DE69623463T2 (da)
DK (1) DK0830348T3 (da)
ES (1) ES2180772T3 (da)
MX (1) MX9708563A (da)
NZ (1) NZ308317A (da)
PT (1) PT830348E (da)
WO (1) WO1996040650A1 (da)
ZA (1) ZA964763B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6191134B1 (en) 1996-06-05 2001-02-20 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US9956968B2 (en) 2014-12-19 2018-05-01 Strato, Inc. Bearing adapter side frame interface for a railway car truck

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な３環性キノキサリンジオン誘導体
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
JPH06228112A (ja) * 1993-02-05 1994-08-16 Yamanouchi Pharmaceut Co Ltd （１ｈ，４ｈ）キノキサリン誘導体
TW260660B (da) * 1993-04-22 1995-10-21 Sumitomo Pharma
WO1994026747A1 (en) * 1993-05-13 1994-11-24 Neurosearch A/S Ampa antagonists and a method of treatment therewith
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
AU5791996A (en) 1996-12-30
US5874426A (en) 1999-02-23
DK0830348T3 (da) 2003-01-06
DE69623463T2 (de) 2003-04-30
WO1996040650A1 (en) 1996-12-19
AU713993B2 (en) 1999-12-16
JP3734275B2 (ja) 2006-01-11
CA2220076A1 (en) 1996-12-19
DE69623463D1 (de) 2002-10-10
KR19990022482A (ko) 1999-03-25
ATE223387T1 (de) 2002-09-15
MX9708563A (es) 1997-12-31
EP0830348A1 (en) 1998-03-25
JPH11506724A (ja) 1999-06-15
NZ308317A (en) 2001-04-27
EP0830348B1 (en) 2002-09-04
ES2180772T3 (es) 2003-02-16
PT830348E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
RU94046067A (ru) Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ лечения
CA2104909A1 (en) Decahydroisoquinolines as excitatory amino acid receptor antagonists
PL323738A1 (en) Amino acid derivatives of substituted derivatives of quinoxalino-2,3-diones as antagonists of glutaminianic receptor
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
ZA964760B (en) Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
ZA964763B (en) Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MXPA02000242A (es) Analogos de 2-aminoindano.
DE69030665D1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino-tetralinderivate
TW288005B (da)
MXPA04003215A (es) Derivados de triazapina como agentes neurotroficos.
CO5310533A1 (es) Derivados de amida de 2,3-dionas de quinoxalina como antago- nistas de receptor de glutamato